HealthLinx signs up South Korean distributor for ovarian cancer Dx
This article was originally published in Clinica
Australian company HealthLinx has made Seoul Clinical Laboratories (SCL) the exclusive distributor of its OvPlex ovarian cancer diagnostic test in South Korea. SCL, said to be South Korea’s largest clinical pathology reference laboratory, will distribute the product once it has gained approval from the South Korea Food and Drug Administration. OvPlex is currently being assessed in a 220-patient study that began earlier this year. Under the terms of the distribution deal, SCL will co-fund the study. Other financial details of the agreement were not disclosed. In South Korea, around 250,000 ovarian cancer tests are performed each year. According to Melbourne-based HealthLinx, the disease is experiencing a 15% annual growth rate in the country. In February, HealthLinx launched OvPlex in the UK through distribution partner Intus Healthcare and has introduced the product in Singapore. At the time of the deal, HealthLinx said that it had opened distribution discussions in other European countries, as well as China.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals